Regarding their medication regimens, the number of patients on hypoglycemia-inducing oral hypoglycemic agents (OHAs), namely, sulfonylureas and meglitinide analogues, insulin, or both, was 36, 215, and 18, respectively. This evidence concerns the gene INS and Hypoglycemia.